-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Benzinga·08/13/2026 12:54:20
Listen to the news
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.